These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 24239912)

  • 1. Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.
    Wang Z; Qian H; Yiu SM; Sun J; Zhu G
    J Inorg Biochem; 2014 Feb; 131():47-55. PubMed ID: 24239912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor.
    Wang B; Qian H; Yiu SM; Sun J; Zhu G
    Eur J Med Chem; 2014 Jan; 71():366-73. PubMed ID: 24361480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells.
    Pavlović M; Tadić A; Gligorijević N; Poljarević J; Petrović T; Dojčinović B; Savić A; Radulović S; Grgurić-Šipka S; Aranđelović S
    J Inorg Biochem; 2020 Sep; 210():111155. PubMed ID: 32768729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of Ru-arene Complexes for Antitumor Drugs.
    Su W; Li Y; Li P
    Mini Rev Med Chem; 2018; 18(2):184-193. PubMed ID: 28494728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.
    Yao H; Ji M; Zhu Z; Zhou J; Cao R; Chen X; Xu B
    Bioorg Med Chem; 2015 Feb; 23(4):681-93. PubMed ID: 25614115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of in vitro absorption in Caco-2 monolayers of anticancer Ru(II)-based complexes acting as dual human topoisomerase and PARP inhibitors.
    de Camargo MS; De Grandis RA; da Silva MM; da Silva PB; Santoni MM; Eismann CE; Menegário AA; Cominetti MR; Zanelli CF; Pavan FR; Batista AA
    Biometals; 2019 Feb; 32(1):89-100. PubMed ID: 30506342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer.
    Zhu Q; Wang X; Hu Y; He X; Gong G; Xu Y
    Bioorg Med Chem; 2015 Oct; 23(20):6551-9. PubMed ID: 26422786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands.
    Zhang Y; Zheng W; Luo Q; Zhao Y; Zhang E; Liu S; Wang F
    Dalton Trans; 2015 Aug; 44(29):13100-11. PubMed ID: 26106875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
    Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
    Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conjugation of a Ru(II) arene complex to neomycin or to guanidinoneomycin leads to compounds with differential cytotoxicities and accumulation between cancer and normal cells.
    Grau-Campistany A; Massaguer A; Carrion-Salip D; Barragán F; Artigas G; López-Senín P; Moreno V; Marchán V
    Mol Pharm; 2013 May; 10(5):1964-76. PubMed ID: 23510087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, Cytotoxicity, and Mechanistic Investigation of Platinum(IV) Anticancer Complexes Conjugated with Poly(ADP-ribose) Polymerase Inhibitors.
    Xu Z; Li C; Zhou Q; Deng Z; Tong Z; Tse MK; Zhu G
    Inorg Chem; 2019 Dec; 58(23):16279-16291. PubMed ID: 31738050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure.
    Canan Koch SS; Thoresen LH; Tikhe JG; Maegley KA; Almassy RJ; Li J; Yu XH; Zook SE; Kumpf RA; Zhang C; Boritzki TJ; Mansour RN; Zhang KE; Ekker A; Calabrese CR; Curtin NJ; Kyle S; Thomas HD; Wang LZ; Calvert AH; Golding BT; Griffin RJ; Newell DR; Webber SE; Hostomsky Z
    J Med Chem; 2002 Nov; 45(23):4961-74. PubMed ID: 12408707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ADP-ribose) polymerase-1 activity facilitates the dissociation of nuclear proteins from platinum-modified DNA.
    Guggenheim ER; Ondrus AE; Movassaghi M; Lippard SJ
    Bioorg Med Chem; 2008 Dec; 16(23):10121-8. PubMed ID: 18977144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of cancer cell growth by ruthenium(II) arene complexes.
    Morris RE; Aird RE; Murdoch Pdel S; Chen H; Cummings J; Hughes ND; Parsons S; Parkin A; Boyd G; Jodrell DI; Sadler PJ
    J Med Chem; 2001 Oct; 44(22):3616-21. PubMed ID: 11606126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation.
    Li H; Hu Y; Wang X; He G; Xu Y; Zhu Q
    Bioorg Med Chem; 2016 Oct; 24(19):4731-4740. PubMed ID: 27561983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
    Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
    Calabrese CR; Batey MA; Thomas HD; Durkacz BW; Wang LZ; Kyle S; Skalitzky D; Li J; Zhang C; Boritzki T; Maegley K; Calvert AH; Hostomsky Z; Newell DR; Curtin NJ
    Clin Cancer Res; 2003 Jul; 9(7):2711-8. PubMed ID: 12855651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold.
    Giannini G; Battistuzzi G; Vesci L; Milazzo FM; De Paolis F; Barbarino M; Guglielmi MB; Carollo V; Gallo G; Artali R; Dallavalle S
    Bioorg Med Chem Lett; 2014 Jan; 24(2):462-6. PubMed ID: 24388690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
    Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
    Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Half-Sandwich Iridium and Ruthenium Complexes: Effective Tracking in Cells and Anticancer Studies.
    Li J; Guo L; Tian Z; Zhang S; Xu Z; Han Y; Li R; Li Y; Liu Z
    Inorg Chem; 2018 Nov; 57(21):13552-13563. PubMed ID: 30289251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.